RepliCel Life Sciences Inc. announced that it will receive $558,837 in funding on December 30, 2022. The company will issue convertible preferred shares in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0428 USD | +4.99% | -.--% | -4.89% |
Apr. 18 | RepliCel Life Sciences Inc. Announces Secured Loan Agreement | CI |
2023 | RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-4.89% | 2.78M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- REPCF Stock
- News RepliCel Life Sciences Inc.
- RepliCel Life Sciences Inc. announced that it expects to receive $0.558837 million in funding